<DOC>
	<DOCNO>NCT02415023</DOCNO>
	<brief_summary>An open-label , dose escalation maximum tolerate dose ( MTD ) and/or recommend phase II dose ( RPTD ) study fruquintinib combine paclitaxel patient advance gastric cancer respond first-line standard chemotherapy .</brief_summary>
	<brief_title>A Phase Ib/2 Clinical Study Fruquintinib Combined With Paclitaxel Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>In dose escalation period , 12-24 patient advance gastric cancer enrol . Patients meet enrollment eligibility receive 28-day cycle fruquintinib 2-5 mg qd combine paclitaxel 80 mg/m2 . Safety information pharmacokinetic data collect till disease progression intolerable toxicity determine MTD and/or RPTD fruquintinib combine paclitaxel patient advance gastric cancer . This period include follow 4 dose group low high : A : Fruquintinib 2 mg qd 3 week follow 1-week break + paclitaxel 80 mg/m2 week first three week cycle B : Fruquintinib 3 mg qd 3 week follow 1-week break + paclitaxel 80 mg/m2 week first three week cycle C : Fruquintinib 4 mg qd 3 week follow 1-week break + paclitaxel 80 mg/m2 week first three week cycle D : Fruquintinib 5 mg qd 3 week follow 1-week break + paclitaxel 80mg/m2 week first three week cycle This study use traditional 3+3 trial design ( 3 subject enrol dose group first . If 1 case DLT observe , additional 3 subject enrol dose group evaluate toxicity ) observe DLT evaluate MTD . If 2 case DLT one dose group , group lower dose group one level MTD dose group . At least 6 subject require MTD dose group confirmation . If MTD achieve end dose escalation 6 subject high dose group , RPTD determine base obtain safety , tolerability , PK efficacy information . Dose escalation study next dose group initiate first treatment cycle ( DLT window observation period ) complete subject safety tolerability confirm dose group ( 0/3 ≤1/6 subject experience DLT ) . Subjects original dose group continue receive next cycle treatment original dose till disease progression treatment withdrawal due follow reason : 1 ) death , 2 ) intolerable toxicity , 3 ) pregnancy , 4 ) investigator considers study terminate subject 's best interest , 5 ) subject legal representative request withdrawal , 6 ) loss follow-up , 7 ) subject poor compliance comply study protocol .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Fully understand study sign inform consent form voluntarily ; 2 . Patients local advance and/or metastatic gastric cancer confirm histology and/or cytology ; 3 . Fail previous firstline standard chemotherapy 4 . Aged 1870years ( inclusive ) ; 5 . Body weight ≥40 kg ; 6 . At least one measurable lesion ( accord RECIST1.1 ) ; 7 . Physical status score ( ECOG score ) 01 ; 8 . Expected survival &gt; 12 week . 1. Who participate another drug clinical trial past 4 week ; receive systemic antitumor chemotherapy , radiotherapy biotherapy within 4 week prior administration study drug ; 2. Who previously receive VEGF/VEGFR inhibitor ; 3. Who recover toxicity cause previous anticancer treatment ( CTCAE &gt; grade 1 ) , completely recover previous surgery ; 4 . Active brain metastasis ( clinical symptom ) ; 5 . Other malignancy except squamouscell basal cell carcinoma , cervical carcinoma situ past 5 year ; 6 . Uncontrolled clinical active infection , e.g . acute pneumonia , hepatitis B active hepatitis C ; 7 . Dysphagia , intractable vomit know drug malabsorption ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>